Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults (Q58436528)

object named as

Michael Marmor

0 references

author name string

Frances H. Priddy

0 references

Deborah Brown

0 references

Kathleen Monahan

0 references

David P. Wright

0 references

Jacob Lalezari

0 references

Steven Santiago

0 references

Michelle Lally

0 references

Richard M. Novak

0 references

Stephen J. Brown

0 references

Priya Kulkarni

0 references

Sheri A. Dubey

0 references

Lisa S. Kierstead

0 references

Danilo R. Casimiro

0 references

Robin Mogg

0 references

Mark J. DiNubile

0 references

John W. Shiver

0 references

Randi Y. Leavitt

0 references

Michael N. Robertson

0 references

Devan V. Mehrotra

0 references

Erin Quirk

Clinical Infectious Diseases

0 references

language of work or name

English

0 references

publication date

June 2008

0 references

published in

0 references

volume

0 references

issue

0 references

page(s)

1769-1781

0 references

cites work

HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary.

1 reference

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

21 January 2018

1 reference

Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study

21 January 2018

1 reference

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

Biological considerations in the development of a human immunodeficiency virus vaccine

21 January 2018

1 reference

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda

21 January 2018

1 reference

The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men

21 January 2018

1 reference

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

21 January 2018

1 reference

Scientific and policy challenges to development of an AIDS vaccine

21 January 2018

1 reference

HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire

21 January 2018

1 reference

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

21 January 2018

1 reference

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

21 January 2018

1 reference

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

21 January 2018

1 reference

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection

21 January 2018

1 reference

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS

21 January 2018

1 reference

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

21 January 2018

1 reference

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

21 January 2018

1 reference

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

21 January 2018

1 reference

Efficient human immunodeficiency virus ( HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate

21 January 2018

1 reference

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

21 January 2018

1 reference

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

21 January 2018

1 reference

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

21 January 2018

1 reference

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

21 January 2018

1 reference

Recombinant Virus Vaccine-Induced SIV-specific CD8 + Cytotoxic T Lymphocytes

21 January 2018

1 reference

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

21 January 2018

1 reference

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

21 January 2018

1 reference

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

21 January 2018

1 reference

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice

21 January 2018

1 reference

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

21 January 2018

1 reference

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses

21 January 2018

1 reference

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

21 January 2018

1 reference

Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase

21 January 2018

1 reference

Site-specific mutagenesis of AIDS virus reverse transcriptase

21 January 2018

1 reference

Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity

21 January 2018

1 reference

Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase

21 January 2018

1 reference

Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function

21 January 2018

1 reference

Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens

21 January 2018

1 reference

Intracellular Staining for HIV-Specific IFN-γ Production: Statistical Analyses Establish Reproducibility and Criteria for Distinguishing Positive Responses

21 January 2018

1 reference

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

21 January 2018

1 reference

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines

21 January 2018

1 reference

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

21 January 2018

1 reference

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

21 January 2018

1 reference

Correlates, surrogates, and vaccines.

21 January 2018

1 reference

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

21 January 2018

1 reference

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

21 January 2018

1 reference